✨ Free AI Report
Terns Pharmaceuticals, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Terns Pharmaceuticals, Inc.
Research Preview

Terns Pharmaceuticals, Inc.: Business Overview, Financials & Competitive Analysis

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company that develops small-molecule product candidates for the treatment of oncology and obesity. The company completed its transition to an oncology compan...

Analyst-debate audio for Terns Pharmaceuticals, Inc.

AskCyborg analysts argue the bull and bear cases for Terns Pharmaceuticals, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Terns Pharmaceuticals, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
8/ 10Strong

Cyborg Score thesis

Clinical-stage oncology company with potentially best-in-disease CML therapy showing strong Phase 1 data, well-funded through...

Read the full analyst-debate transcript →
Industry Biopharmaceutical/Clinical-Stage Oncology
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: June 15, 2026
AI-Verified Research
30+ Page Report

Get the Latest Terns Pharmaceuticals, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Terns Pharmaceuticals, Inc. Overview

Pro stress-test →

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company that develops small-molecule product candidates for the treatment of oncology and obesity. The company completed its transition to an oncology company anchored by TERN-701, an allosteric BCR-ABL inhibitor for chronic myeloid leukemia (CML).

Strategic Profile

Pro stress-test →

TERN-701 is a highly selective allosteric BCR-ABL inhibitor with a potentially best-in-disease profile that could meaningfully improve upon the efficacy, safety and convenience of existing CML treatments. The Phase 1 CARDINAL trial showed a 75% cumulative major molecular response (MMR) rate by 24 weeks with 100% MMR durability and encouraging safety across doses.

Competitive Landscape

Pro stress-test →

TERN-701 is positioned against second-generation TKI competitors including dasatinib, nilotinib, and bosutinib in planned pivotal trials. The allosteric mechanism and enhanced safety profile offer potential differentiation in the CML treatment space. Multiple phase-appropriate clinical candidates are in development at competing biotech and established pharmaceutical companies.

Industry Context

Terns Pharmaceuticals, Inc. operates in Biopharmaceutical/Clinical-Stage Oncology.

Key facts

Founded: 2015 · Headquarters: Foster City, United States · Market cap: $3.4B

What the analysts stress-tested

The top findings that survived the multi-agent debate for Terns Pharmaceuticals, Inc..

+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Terns Pharmaceuticals, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

DasatinibSecond-generation BCR-ABL tyrosine kinase inhibitor for CML→NilotinibSecond-generation BCR-ABL tyrosine kinase inhibitor for CML→BosutinibSecond-generation BCR-ABL tyrosine kinase inhibitor for CML→

Compare Terns Pharmaceuticals, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Terns Pharmaceuticals, Inc. operates in Biopharmaceutical/Clinical-Stage Oncology. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical/Clinical-Stage Oncology research →
NEW · MCP server

Ask your AI assistant about Terns Pharmaceuticals, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Terns Pharmaceuticals, Inc. and its top competitor on Cyborg Score”
“What did Terns Pharmaceuticals, Inc. do this quarter?”
“Is Terns Pharmaceuticals, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Terns Pharmaceuticals, Inc. do?+
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company that develops small-molecule product candidates for the treatment of oncology and obesity. The company completed its transition to an oncology compan...
What is Terns Pharmaceuticals, Inc.'s Cyborg Score?+
Terns Pharmaceuticals, Inc. has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Terns Pharmaceuticals, Inc.'s main competitors?+
Named competitors include Dasatinib, Nilotinib, Bosutinib. The full competitive landscape is in the AskCyborg report.
How can I get the full Terns Pharmaceuticals, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Terns Pharmaceuticals, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Terns Pharmaceuticals, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

Other strong performers across the analyst-debate framework. Click any to see their research report.

9Anthropic9Dubai Electricity and Water Authority (DEWA)9Emaar Development PJSC9Gold Fields Limited9Western Digital Corporation9Advantest Corporation9Fast Retailing Co., Ltd.9JPMorgan Chase & Co.9Siemens AG9Space Exploration Technologies Corp8Arcellx, Inc.8Gentili Mosconi S.p.A.8Neurogene Inc.8Selvaag Bolig ASA8Satellogic Inc.8Klaveness Combination Carriers ASA8Unusual Machines, Inc.8Shoei Co., Ltd.